Dr. Hoenle AG (GB:0O27)
LSE:0O27
0O27 Stock Chart & Stats
€8.12
-€0.14(-1.99%)
At close: 4:00 PM EST
€8.12
-€0.14(-1.99%)
Day’s Range― - ―
52-Week Range€6.70 - €11.70
Previous CloseN/A
Volume1.10K
Average Volume (3M)689.00
Market Cap
€58.56M
Enterprise Value€99.64M
Total Cash (Recent Filing)€6.71M
Total Debt (Recent Filing)€47.80M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding6,062,930
10 Day Avg. Volume2,033
30 Day Avg. Volume689
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€100.27M
Bulls Say, Bears Say
Bulls Say
Positive Free Cash FlowSustained positive operating and free cash flow provides a durable internal funding source to support working capital, maintenance capex and selective investment in product development. That reduces near-term reliance on external financing and helps the business weather cyclical troughs.
Manageable LeverageDebt at ~0.63x equity indicates the balance sheet is not overlevered, giving the company financial flexibility to fund growth or cover setbacks. Manageable leverage lowers solvency risk and preserves optionality for investment in product upgrades or aftermarket expansion.
Recurring Aftermarket And Diversified Product MixA business model built on initial system sales plus recurring consumables, replacement lamps and measurement instruments creates durable, higher-visibility revenue from an installed base. Diversified product lines across curing, disinfection, measurement and lamps reduce concentration risk.
Bears Say
Persistent UnprofitabilityOngoing net losses and negative operating profitability indicate the company has not yet demonstrated consistent earnings power. Continued losses erode equity, constrain reinvestment capacity and mean management must sustain improvement to convert revenue growth into durable profits.
Exposure To Industrial Capex CyclesHeavy reliance on industrial capital expenditure for new-system sales makes revenue cyclically sensitive to macro and sector capex budgets. While aftermarket buffers some volatility, prolonged capex weakness can materially reduce new-system orders and slow structural growth.
Historic Cash-flow VolatilityPast episodes of negative operating and free cash flow demonstrate that cash generation can swing materially. That inconsistency raises execution and planning risk: occasional cash shortfalls could force external funding or delay strategic investments despite recent positive FCF.
Dr. Hoenle AG News
0O27 FAQ
What was Dr. Hoenle AG’s price range in the past 12 months?
Dr. Hoenle AG lowest share price was €6.70 and its highest was €11.70 in the past 12 months.
What is Dr. Hoenle AG’s market cap?
Dr. Hoenle AG’s market cap is €58.56M.
When is Dr. Hoenle AG’s upcoming earnings report date?
Dr. Hoenle AG’s upcoming earnings report date is May 19, 2026 which is in 40 days.
How were Dr. Hoenle AG’s earnings last quarter?
Dr. Hoenle AG released its earnings results on Feb 24, 2026. The company reported -€0.25 earnings per share for the quarter, missing the consensus estimate of -€0.214 by -€0.036.
Is Dr. Hoenle AG overvalued?
According to Wall Street analysts Dr. Hoenle AG’s price is currently Overvalued.
Does Dr. Hoenle AG pay dividends?
Dr. Hoenle AG pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Dr. Hoenle AG dividends here
What is Dr. Hoenle AG’s EPS estimate?
Dr. Hoenle AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dr. Hoenle AG have?
Dr. Hoenle AG has 6,062,930 shares outstanding.
What happened to Dr. Hoenle AG’s price movement after its last earnings report?
Dr. Hoenle AG reported an EPS of -€0.25 in its last earnings report, missing expectations of -€0.214. Following the earnings report the stock price went up 8.421%.
Which hedge fund is a major shareholder of Dr. Hoenle AG?
Currently, no hedge funds are holding shares in GB:0O27
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Hoenle AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.78%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
-7.47%
Trailing 12-Months
Company Description
Dr. Hoenle AG
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.
Technical Analysis
LPKF Laser & Electronics
―
Manz AG
―
MAX Automation
―
Singulus Technologies
―
Suss Microtec
―
Options Prices
Currently, No data available
---